Floatz logo

su011248

Metastatic Prostate Cancer

US Oncology ResearchPhase 2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
73/ 100

Competitive context

60 Active assets in the Metastatic Prostate Cancer cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
Mayo Clinic
Phase 4BBB
Sipuleucel-T
Yale University
Phase 2BB
Degarelix
Praful Ravi, MB BCHir, MRCP
Phase 3BB
Apalutamide
AstraZeneca
Phase 4BB
PIFLUFOLASTAT
Brigham and Women's Hospital
Phase 4BB

View all 50 →

Same molecule, other indications

su011248 is also rated in:

Gastrointestinal Stromal TumorsDormant
BBB
Indicative ·
75 / 100
View asset →
Pancreatic Neuroendocrine TumorDormant
BB
Indicative ·
69 / 100
View asset →
Renal Cell CarcinomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →